Medscape InDiscussion: Breast Cancer and HER2

Drs Kathy Miller and Lajos Pusztai discuss predicting which patients will have a PCR, and the impact this has on new treatments or reducing the intensity of treatments. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002987. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is in...

Drs Kathy Miller and Sunil Badve discuss how HER2 testing has evolved over time as the need for that clinical testing has shifted, including assay limits, biology, and clinical impact. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002986. The topics and discussions are planned, produced, and reviewed independently of advertisers. Th...

Drs Kathy Miller and Erika Hamilton discuss ILD linked to ADCs, highlighting early symptoms, key CT findings, pulmonary collaboration, steroid management, and ongoing vigilance. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002985. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podc...

Drs Kathy Miller and Sara Tolaney discuss changes in the management of first-line metastatic HER2-positive disease and the DESTINY-Breast09 trial results. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002984. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only fo...

Drs Kathy Miller and Alexandra Thomas discuss important toxicities for breast cancer HER2-targeted therapies and how to improve the patient experience. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002982. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for U...

Drs Kathy Miller and Bonnie Ky discuss cardiovascular concerns with HER2-targeted therapies and how to work with cardiology colleagues for the best treatment outcomes. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002981. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is int...

Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2–ultra-low breast cancer. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001338. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcar...

Kathy D. Miller, MD, and Stephanie L. Graff, MD, discuss sequencing of ADCs for metastatic HER2-low breast cancer including sequencing, toxicities, and clinical trials. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001337. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is in...

Drs Kathy Miller and Nancy U. Lin discuss central nervous system involvement in HER2-positive breast cancer, including the biology and management of patients. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001336. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended onl...

Drs Kathy D. Miller and Heather A. Parsons explore the complexities and evolving strategies in managing HER2+ oligometastatic breast cancer, tackling curative intent, treatment duration, and the promise of emerging biomarkers. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001335. The topics and discussions are planned, produced, and...

Drs Kathy D. Miller and Sunil S. Badve discuss the importance of identifying HER2-low patients, those with ultra-low staining, and the benefit of targeted ADCs. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001160. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended o...

Drs Kathy D. Miller and Sara M. Tolaney discuss advancements and considerations for optimizing treatment for HER2-positive breast cancer, focusing on balancing efficacy with minimizing toxicity. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001124. The topics and discussions are planned, produced, and reviewed independently of adver...